Identifier-confirmed and citation-only records have not passed evidence or citation verification. These checks do not establish evidence strength, efficacy, safety, or suitability.
Read each study in its experimental context. A shared molecule name or database link does not establish that our material matches a study's formulation, composition or preparation. Study findings are not measurements of our inventory, promises of a biological result or authorization to use our materials in humans or animals. Actual Product specifications and lot reports are separate records.
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The present study aimed to investigate the wound healing effects of synthesized BPC-157 on alkali-burned rats and elucidate its mechanisms of action.
Study design
Not reported in the declared source.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Male Sprague Dawley rats (n=58) weighing 160 g–220 g were chosen for the experiments.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
To assess the influence of BPC-157 on cell growth, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay was used.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Jejunal tissue preparations were apically and basolaterally treated with 5, 30, and 150 μM clotrimazole (CLT) or vehicle control for 20 minutes in Ussing chambers and subsequently challenged with the cAMP-dependent secretagogue VIP (7.5 nm) or the Ca2+-dependent secretagogue carbachol (20 μM).
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
To this goal, VIP content and/or activity were modulated in vivo and the impact on osteoblast activity and expression of NGF and sema3a was determined.
Participants or experimental system
Eight weeks-old male Wistar rats (Iffa Credo, L’Arbresle, France), weighing 250 ± 20 g, fed a standard rodent diet (M25 Extralabo; UAR, Villemoisson, France) were used.
Study scale
Forty 8 weeks-old rats were distributed at random in two lots.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Twenty rats were sham-treated with daily saline ip injections and used as controls.
Outcomes examined
In the non-osteogenic compartment, we quantified (a) the number of ßNGF+ mast cells (N/mm of adjacent bone surface).
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
While these data show that the cholinergic innervation significantly impacts osteoblastic cell behavior, how these cells act on the fibers innervating the periosteum remains unknown.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
As a feasibility study, a primary purpose was to evaluate the design and methodology.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The purpose of this study is to evaluate the whether Tβ4 can be used as a vascular-protective agent.
Study design
To corroborate the in vivo studies, we performed our analysis using lung microvascular endothelial cells (MVEC) stimulated with TGFβ1.
Participants or experimental system
Twelve-week-old male mice (∼25 g) were used for experiments.
Study scale
A total of six mice were studied in each group.
Intervention or exposure
Briefly, wild-type (WT) mice received an intraperitoneal (i.p) injection of MCT (80 mg/kg body wt) every 20 days for 3 times.
Comparator
Age- and sex-matched WT with normal saline-injected mice of C57BL/6 background served as controls.
Outcomes examined
The pathogenesis of MCT-induced PH was evaluated through RV pressure measurement.
Key findings
In monocrotaline (MCT)-induced PH mouse model, we showed that mice treated with Tβ4 significantly attenuated the systolic pressure and RVH, compared to the MCT treated mice.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Study scale: A total of 24 Tau/GSK3β tg mice (3 month (m) old; n = 12 CBL treated and n = 12 saline) and 24 non tg mice (3 m old; n = 12 CBL treated and n = 12 saline) were utilized.
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
For this purpose we sought to investigate the effects of CBL in a tg model of tauopathy.
Study design
Not reported in the declared source.
Participants or experimental system
Accordingly, double tg mice expressing mutant Tau under the mThy-1 promoter and GSK3β (to enhance Tau phosphorylation) were treated with CBL and evaluated neuropathologically.
Study scale
A total of 24 Tau/GSK3β tg mice (3 month (m) old; n = 12 CBL treated and n = 12 saline) and 24 non tg mice (3 m old; n = 12 CBL treated and n = 12 saline) were utilized.
Intervention or exposure
Animals were treated beginning at 3 months of age for 3 months, because at the earlier age group the Tau pathology was subtler, becoming progressively worse at 6 and 12 months of age.
Comparator
By immunoblot, levels of t-Tau were elevated in the Tau/GSK3β bigenic mice compared to the non-tg, no effects of CBL administration on t-Tau were observed (Figure 3A-D).
Outcomes examined
Non-tg and bigenic mice were treated for 3 months (beginning at 3 months of age) with CBL and brains were analyzed with p-tau antibodies.
Key findings
CBL treatment reduced the levels of Tau phosphorylation in the dentate gyrus and the degeneration of pyramidal neurons in the temporal cortex and hippocampus of the Tau/GSK3β double tg mice.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Narrative review · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not reported in the declared source.
Participants or experimental system
Not reported in the declared source.
Study scale
Not reported in the declared source.
Intervention or exposure
Not reported in the declared source.
Comparator
Not reported in the declared source.
Outcomes examined
Not reported in the declared source.
Key findings
Oxytocin may thus play a role similar to other modulators of NMDA receptor function, in mediating top down modulation, not only in the cortex, but also in the autonomic nervous system and associated subcortical regions of the brain.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
We also evaluated HN action on the proapoptotic effect of TNF-α in anterior pituitary cells assessed by the TUNEL method.
Study design
Not reported in the declared source.
Participants or experimental system
Adult Wistar female and male rats were kept in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Study scale
Not reported in the declared source.
Intervention or exposure
Sliced fragments were dispersed enzymatically by successive incubations in DMEM-S-BSA, containing 0.75% trypsin, 10% fetal bovine serum (FBS) previously treated with 0.025% dextran-0.25% charcoal (FBS-DCC) to remove steroids and 45 U/µl deoxyribonuclease type I (Invitrogen).
Comparator
Rats were ovariectomized (OVX), orquidectomized (GNX) or sham-operated two weeks before experiments.
Outcomes examined
The presence of HNr in pituitary sections and dispersed anterior pituitary cells was evaluated by indirect immunofluorescent staining.
Key findings
In the present work, we demonstrated by immunocytochemical analysis and flow cytometry the expression of HNr in the anterior pituitary of female and male adult rats as well as in pituitary tumor GH3 cells.
Limitations and uncertainty
The mechanism by which HN protects anterior pituitary cells from proapoptotic stimuli, not examined in the present study, remains to be determined.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The trial is to evaluate whether Tα1 improves 28-day all-cause mortality rates and immunofunction in patients with severe sepsis.
Study design
We performed a multicenter randomized controlled trial in six tertiary, teaching hospitals in China between May 12, 2008 and Dec 22, 2010.
Participants or experimental system
Eligible patients admitted in ICU with severe sepsis were randomly allocated by a central randomization center to the control group or Tα1 group (1:1 ratio).
Study scale
A total of 361 patients were allocated to either the control group (n = 180) or Tα1 (n = 181) group.
Intervention or exposure
In the Tα1 group, patients received subcutaneous injections of 1.6 mg Tα1 (ZADAXIN™, SciClone Pharmaceuticals, Foster City, CA, USA) twice per day for five consecutive days, then once per day for two consecutive days.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
The primary outcome was death from any cause and was assessed 28 days after enrollment.
Key findings
Greater improvement of mHLA-DR was observed in the Tα1 group on day 3 (mean difference in mHLA-DR changes between the two groups was 3.9%, 95% CI 0.2 to 7.6%, P = 0.037) and day 7 (mean difference in mHLA-DR changes between the two groups was 5.8%, 95% CI 1.0 to 10.5%, P = 0.017) than in the control group.
Limitations and uncertainty
In our study, several factors limit the extent to which the results can be generalized.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Study scale: One week after transduction, strong signal was evident in neurons across the SCN and overall fluorescence was highly circadian, with estimated [Ca2+]i ranging between 113 ± 7.5nM (nadir) and 191 ± 25nM (zenith, mean ± SEM n = 3, see Experimental Procedures; Figure 4A; Movie S2).
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Having characterized this program, and shown its dependence upon neuropeptidergic G-coupled signaling, we then sought to examine causal relationships within it.
Study design
Not reported in the declared source.
Participants or experimental system
VIP-IRESCre (Viptm1(cre)Zjh/J) and R26 floxed STOP EYFP (B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J) mice were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA).
Study scale
One week after transduction, strong signal was evident in neurons across the SCN and overall fluorescence was highly circadian, with estimated [Ca2+]i ranging between 113 ± 7.5nM (nadir) and 191 ± 25nM (zenith, mean ± SEM n = 3, see Experimental Procedures; Figure 4A; Movie S2).
Intervention or exposure
Not reported in the declared source.
Comparator
Vehicle treated SCN received ddH2O as vehicle treatment.
Outcomes examined
To test this, the spatiotemporal dynamics of Per2:luc and Cry1-luc expression were analyzed.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
In the present study, we aimed to evaluate the vasodilatory potential of the synthetic, stable VIP analog RO 25-1553 in the pulmonary circulation.
Study design
In a second set of experiments, we tested whether RO 25-1553 exerts a similar vasodilatory effect in the pulmonary vasculature when a) administered by inhalation and b) in an in vivo setting rather than an isolated organ preparation.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not reported in the declared source.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Plaque specimens from 34 patients undergoing carotid endarterectomy were classified according to symptomatic history.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not reported in the declared source.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked